<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716039</url>
  </required_header>
  <id_info>
    <org_study_id>RP1204</org_study_id>
    <nct_id>NCT01716039</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)</brief_title>
  <official_title>A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination With Methotrexate for the Treatment of Patients With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the body's reaction to dose-response relationship for the adalimumab/Methotrexate
      interaction in subjects with moderately to severely active ulcerative colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the Pharmacokinetic dose-response relationship for the adalimumab/Methotrexate
      interaction in subjects with moderately to severely active UC.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Analysis (PK) will measure antidrug antibodies (ADAs)and plasma concentrations of adalimumab and methotrexate.</measure>
    <time_frame>20 weeks</time_frame>
    <description>PK parameters will include:
Maximum plasma concentration (Cmax)
Time to reach Cmax (Tmax)
Area under the concentration time curve (AUC)
Elimination rate constant (k) Elimination half-life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and Endoscopic Evaluation of the Efficacy of Combination Therapy</measure>
    <time_frame>20 weeks</time_frame>
    <description>The primary efficacy outcome will be assessed by comparing the change in the modified Baron score from baseline to the final visit between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify covariates</measure>
    <time_frame>20 weeks</time_frame>
    <description>To identify covariates (gender, weight, BMI, albumin, TNF, CRP, disease severity, concomitant medications) that might influence the clearance and or disposition of adalimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between PK and efficacy</measure>
    <time_frame>20 weeks</time_frame>
    <description>To evaluate the relationship between PK and efficacy (PD)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>MTX 12.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX 12.5</intervention_name>
    <description>once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or &gt;9).
Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab</description>
    <arm_group_label>MTX 12.5</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX 25</intervention_name>
    <description>once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or &gt;9).
Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab</description>
    <arm_group_label>MTX 25 mg</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subjects will receive 18 weekly doses of adalimumab</description>
    <arm_group_label>MTX 12.5</arm_group_label>
    <arm_group_label>MTX 25 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating females. Females of child bearing potential must
             have a negative serum pregnancy test prior to randomization, and must use a hormonal
             (oral, implantable or injectable) or barrier method of birth control throughout the
             study. Females unable to bear children must have documentation of such in the source
             records (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum
             of one year since the last menstrual period]).

          -  Diagnosis of UC confirmed by established criteria, regardless of disease duration.

          -  Moderate to severely active UC, defined by a modified Mayo Score ≥6, with confirmed
             endoscopic activity by central reader (Mayo endoscopic subscore ≥2).

          -  Require initiation with adalimumab for induction of remission.

          -  Ability of subject to swallow study drug capsules.

          -  Ability of subject to participate fully in all aspects of this clinical trial.

          -  Written informed consent must be obtained and documented.

        Exclusion Criteria:

          -  Prior treatment with a TNF antagonist or biological therapy.

          -  Prior treatment with MTX.

          -  Disease limited to the rectum (proctitis).

          -  Documented presence of antibodies against adalimumab.

          -  Contraindication for anti-TNF or MTX therapy.

          -  Contraindication for endoscopy.

          -  Ostomy.

          -  Planned surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Feagan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robarts Research Institute - Western University</affiliation>
  </overall_official>
  <reference>
    <citation>Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76. Erratum in: N Engl J Med. 2006 May 18;354(20):2200.</citation>
    <PMID>16339095</PMID>
  </reference>
  <reference>
    <citation>Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May;142(5):1102-1111.e2. doi: 10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8.</citation>
    <PMID>22326435</PMID>
  </reference>
  <reference>
    <citation>Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780-7. doi: 10.1136/gut.2010.221127. Epub 2011 Jan 5.</citation>
    <PMID>21209123</PMID>
  </reference>
  <reference>
    <citation>Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601-8.</citation>
    <PMID>12584368</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderately to severely active Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

